JAFFE ROSS A MD 4/A

Accession 0000899243-22-005656

CIK 0001452965other

View on SEC.gov Company Profile

Filed

Feb 9, 7:00 PM ET

Accepted

Feb 10, 7:18 PM ET

Size

76.7 KB

Accession

0000899243-22-005656

Insider Transaction Report

Form 4/AAmended

Period: 2021-10-26

MINERVA SURGICAL INCUTRS

JAFFE ROSS A MD

Director

Transactions

Conversion
Series D Preferred Stock
2021-10-26−3,148→ 0 total(indirect: See Footnote)
→ Common Stock (3,148 underlying)
Conversion
Subordinated Secured Convertible Promissory Note
2021-10-26−787,049.83→ 0 total(indirect: See Footnote)
Exercise: $11.31→ Series D Preferred Stock (69,613 underlying)
Conversion
Subordinated Secured Convertible Promissory Note
2021-10-26−5,154.72→ 0 total(indirect: See Footnote)
Exercise: $11.31→ Series D Preferred Stock (455 underlying)
Conversion
Subordinated Secured Convertible Promissory Note
2021-10-26−4,958.05→ 0 total(indirect: See Footnote)
Exercise: $11.31→ Series D Preferred Stock (438 underlying)
Conversion
Subordinated Secured Convertible Promissory Note
2021-10-26−4,888.35→ 0 total(indirect: See Footnote)
Exercise: $11.31→ Series D Preferred Stock (432 underlying)
Conversion
Series D Preferred Stock
2021-10-26+73,816→ 284,437 total(indirect: See Footnote)
→ Common Stock (73,816 underlying)
Conversion
Series D Preferred Stock
2021-10-26+438→ 893 total(indirect: See Footnote)
→ Common Stock (438 underlying)
Conversion
Series D Preferred Stock
2021-10-26+432→ 1,325 total(indirect: See Footnote)
→ Common Stock (432 underlying)
Conversion
Series D Preferred Stock
2021-10-26−72,374→ 212,063 total(indirect: See Footnote)
→ Common Stock (72,374 underlying)
Conversion
Series D Preferred Stock
2021-10-26−438→ 896 total(indirect: See Footnote)
→ Common Stock (438 underlying)
Conversion
Common Stock
2021-10-26+10,473→ 10,473 total(indirect: See Footnote)
Conversion
Series C Preferred Stock
2021-10-26−878,947→ 0 total(indirect: See Footnote)
→ Common Stock (878,947 underlying)
Conversion
Series D Preferred Stock
2021-10-26−499,843→ 0 total(indirect: See Footnote)
→ Common Stock (499,843 underlying)
Conversion
Subordinated Secured Convertible Promissory Note
2021-10-26−818,269.09→ 0 total(indirect: See Footnote)
Exercise: $11.31→ Series D Preferred Stock (72,374 underlying)
Conversion
Series D Preferred Stock
2021-10-26−69,613→ 142,450 total(indirect: See Footnote)
→ Common Stock (69,613 underlying)
Conversion
Series D Preferred Stock
2021-10-26−432→ 464 total(indirect: See Footnote)
→ Common Stock (432 underlying)
Conversion
Common Stock
2021-10-26+1,663,227→ 1,663,227 total(indirect: See Footnote)
Conversion
Series C Preferred Stock
2021-10-26−5,536→ 0 total(indirect: See Footnote)
→ Common Stock (5,536 underlying)
Conversion
Subordinated Secured Convertible Promissory Note
2021-10-26−775,985.84→ 0 total(indirect: See Footnote)
Exercise: $11.31→ Series D Preferred Stock (68,634 underlying)
Conversion
Subordinated Secured Convertible Promissory Note
2021-10-26−834,568.37→ 0 total(indirect: See Footnote)
Exercise: $11.31→ Series D Preferred Stock (73,816 underlying)
Conversion
Subordinated Secured Convertible Promissory Note
2021-10-26−5,257.39→ 0 total(indirect: See Footnote)
Exercise: $11.31→ Series D Preferred Stock (464 underlying)
Conversion
Series D Preferred Stock
2021-10-26+72,374→ 72,374 total(indirect: See Footnote)
→ Common Stock (72,374 underlying)
Conversion
Series D Preferred Stock
2021-10-26+69,613→ 141,987 total(indirect: See Footnote)
→ Common Stock (69,613 underlying)
Conversion
Series D Preferred Stock
2021-10-26+68,634→ 210,621 total(indirect: See Footnote)
→ Common Stock (68,634 underlying)
Conversion
Series D Preferred Stock
2021-10-26+455→ 455 total(indirect: See Footnote)
→ Common Stock (455 underlying)
Conversion
Series D Preferred Stock
2021-10-26+464→ 1,789 total(indirect: See Footnote)
→ Common Stock (464 underlying)
Conversion
Series D Preferred Stock
2021-10-26−68,634→ 73,816 total(indirect: See Footnote)
→ Common Stock (68,634 underlying)
Conversion
Series D Preferred Stock
2021-10-26−73,816→ 0 total(indirect: See Footnote)
→ Common Stock (73,816 underlying)
Conversion
Series D Preferred Stock
2021-10-26−455→ 1,334 total(indirect: See Footnote)
→ Common Stock (455 underlying)
Conversion
Series D Preferred Stock
2021-10-26−464→ 0 total(indirect: See Footnote)
→ Common Stock (464 underlying)

Footnotes (11)

[F1]The Series C Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
[F10]Represents $4,888.35 of outstanding principal and interest calculated through October 26, 2021, on which date such amount converted into shares of Series D Preferred Stock at a conversion price per share of $11.30602.
[F11]Represents $5,257.39 of outstanding principal and interest calculated through October 26, 2021, on which date such amount converted into shares of Series D Preferred Stock at a conversion price per share of $11.30602.
[F2]The securities are held by Versant Venture Capital IV, L.P. ("Versant IV"). Versant Ventures IV, LLC ("Versant Ventures IV GP") is the general partner of Versant IV. The Reporting Person is a managing director of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant IV; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.
[F3]The securities are held by Versant Side Fund IV, L.P. ("Versant Side Fund IV"). Versant Ventures IV GP is the general partner of Versant Side Fund IV. The Reporting Person is a managing director of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant Side Fund IV; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.
[F4]Represents $818,269.09 of outstanding principal and interest calculated through October 26, 2021, on which date such amount converted into shares of Series D Preferred Stock at a conversion price per share of $11.30602.
[F5]Represents $787,049.83 of outstanding principal and interest calculated through October 26, 2021, on which date such amount converted into shares of Series D Preferred Stock at a conversion price per share of $11.30602.
[F6]Represents $775,985.84 of outstanding principal and interest calculated through October 26, 2021, on which date such amount converted into shares of Series D Preferred Stock at a conversion price per share of $11.30602.
[F7]Represents $834,568.37 of outstanding principal and interest calculated through October 26, 2021, on which date such amount converted into shares of Series D Preferred Stock at a conversion price per share of $11.30602.
[F8]Represents $5,154.72 of outstanding principal and interest calculated through October 26, 2021, on which date such amount converted into shares of Series D Preferred Stock at a conversion price per share of $11.30602.
[F9]Represents $4,958.05 of outstanding principal and interest calculated through October 26, 2021, on which date such amount converted into shares of Series D Preferred Stock at a conversion price per share of $11.30602.

Documents

1 file

4
doc4a.xml
FORM 4/A SUBMISSION

Issuer

MINERVA SURGICAL INC

CIK 0001452965

→

Entity typeother

Related Parties

filerCIK 0001181338

Filing Metadata

Form type: 4/A
Filed: Feb 9, 7:00 PM ET
Accepted: Feb 10, 7:18 PM ET
Size: 76.7 KB

View on SEC.gov